S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
Log in

NASDAQ:DARE - Dare Bioscience Stock Price, Forecast & News

$0.81
-0.02 (-2.41 %)
(As of 12/12/2019 04:00 PM ET)
Today's Range
$0.80
Now: $0.81
$0.87
50-Day Range
$0.74
MA: $0.81
$0.89
52-Week Range
$0.60
Now: $0.81
$3.25
Volume146,406 shs
Average Volume474,190 shs
Market Capitalization$13.51 million
P/E RatioN/A
Dividend YieldN/A
Beta1.83
Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DARE
CUSIPN/A
Phone858-926-7655

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.59 per share

Profitability

Net Income$-16,740,000.00

Miscellaneous

Employees5
Market Cap$13.51 million
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable

Receive DARE News and Ratings via Email

Sign-up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter.


Dare Bioscience (NASDAQ:DARE) Frequently Asked Questions

What is Dare Bioscience's stock symbol?

Dare Bioscience trades on the NASDAQ under the ticker symbol "DARE."

How were Dare Bioscience's earnings last quarter?

Dare Bioscience Inc (NASDAQ:DARE) announced its quarterly earnings data on Thursday, November, 14th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.21) by $0.01. View Dare Bioscience's Earnings History.

When is Dare Bioscience's next earnings date?

Dare Bioscience is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Dare Bioscience.

What price target have analysts set for DARE?

2 brokerages have issued 12-month price targets for Dare Bioscience's shares. Their forecasts range from $3.00 to $3.00. On average, they expect Dare Bioscience's share price to reach $3.00 in the next year. This suggests a possible upside of 270.4% from the stock's current price. View Analyst Price Targets for Dare Bioscience.

What is the consensus analysts' recommendation for Dare Bioscience?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dare Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dare Bioscience.

Has Dare Bioscience been receiving favorable news coverage?

News articles about DARE stock have been trending extremely negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Dare Bioscience earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an impact on the company's share price in the immediate future. View News Stories for Dare Bioscience.

Are investors shorting Dare Bioscience?

Dare Bioscience saw a decrease in short interest during the month of November. As of November 29th, there was short interest totalling 755,600 shares, a decrease of 13.8% from the November 14th total of 876,300 shares. Based on an average trading volume of 232,300 shares, the short-interest ratio is presently 3.3 days. Currently, 4.6% of the shares of the stock are short sold. View Dare Bioscience's Current Options Chain.

Who are some of Dare Bioscience's key competitors?

What other stocks do shareholders of Dare Bioscience own?

Who are Dare Bioscience's key executives?

Dare Bioscience's management team includes the folowing people:
  • Ms. Sabrina Martucci Johnson, Pres, CEO, Sec. & Director (Age 52)
  • Ms. Lisa Walters-Hoffert, Chief Financial Officer (Age 60)
  • Mr. Mark Walters, VP of Operations (Age 64)
  • Ms. MarDee J. Haring-Layton, VP of Accounting & Fin. (Age 43)
  • Dr. David Friend, Chief Scientific Officer

How do I buy shares of Dare Bioscience?

Shares of DARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Dare Bioscience's stock price today?

One share of DARE stock can currently be purchased for approximately $0.81.

How big of a company is Dare Bioscience?

Dare Bioscience has a market capitalization of $13.51 million. The biotechnology company earns $-16,740,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. Dare Bioscience employs 5 workers across the globe.View Additional Information About Dare Bioscience.

What is Dare Bioscience's official website?

The official website for Dare Bioscience is http://www.darebioscience.com/.

How can I contact Dare Bioscience?

Dare Bioscience's mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The biotechnology company can be reached via phone at 858-926-7655 or via email at [email protected]


MarketBeat Community Rating for Dare Bioscience (NASDAQ DARE)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  287 (Vote Outperform)
Underperform Votes:  209 (Vote Underperform)
Total Votes:  496
MarketBeat's community ratings are surveys of what our community members think about Dare Bioscience and other stocks. Vote "Outperform" if you believe DARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DARE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Featured Article: Do Tariffs Work?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel